Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm

Change Agents

20/04/2020 14:37

** Shares of biotech developer  AVCO.O  jump 23% to $1.73
    ** Co says it has achieved milestones in therapeutic program
to combat cytokine storm, where in small protein molecules that
regulate physiological functions are released in excess in
life-threatening diseases
    ** The cytokine storm is also associated with COVID-19 lung
damage  urn:newsml:reuters.com:*:nGNX4xW2zw
    ** Co says its AVA-Trap therapeutic program, co-developed
with Massachusetts Institute of Technology (MIT), is entering
animal model testing   
    ** Up to last close, AVCO down 27.98% YTD  

 (Reporting by Vishwadha Chander in Bengaluru)
 ((vishwadha.chander@thomsonreuters.com))